Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer’s Reinhardt Returning To Novartis To Replace Departing Vasella

This article was originally published in The Pink Sheet Daily

Executive Summary

Novartis says long-time chairman Daniel Vasella has decided to leave the Swiss drug maker and its board has chosen former COO and current Bayer healthcare division head Jorg Reinhardt to replace him.

Advertisement

Related Content

CHMP Rejects Serelaxin But Clears Albiglutide, Riociguat And Lurasidone
Bayer Taps Pfizer Emerging Markets Head To Lead Health Care Division
Bayer Names Pfizer’s Brandicourt Healthcare Division CEO
Bayer Sees Xarelto Being Profitable In 2014 As New Drugs Deliver
Bayer’s Eylea Sees Good Start In Japan Thanks To Partnering
Partnering Key To Bayer’s Eylea Good Start In Japan
AstraZeneca’s Executive Shakeup Includes Global Strategist To Be Named Later
For Novartis, 2012 Is Set To Be A Bumpy Ride
With 100% Alcon Ownership, Novartis Forms New Eye Care Unit
Novartis Splits Chair and CEO Positions, Names Joe Jimenez CEO

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS074799

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel